Japan Aligns Generic Drug Regulation With ICH Standards-What This Means for Global Pharma?

 

Regulatory Affairs Services for Generics in Japan

Japan’s Ministry of Health, Labour & Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA) have taken a major step in harmonising generic drug regulation with International Council for Harmonisation (ICH) quality expectations. This shift extends key ICH guidelines including stability (e.g., ICH Q1 series) and impurity standards to generic pharmaceutical submissions in Japan.

Why this matters:
✔️ Generic drug dossiers now must include ICH-aligned quality data, including long-term stability studies tailored to Japan’s climatic conditions.
✔️ Applicants must use the ICH CTD structure (Modules 2 & 3) for consistency with global submissions.
✔️ Early PMDA engagement is key for clarifying expectations and avoiding review delays.

Strategic impact for manufacturers:
✔️ Drives regulatory convergence with major markets (US, EU, etc.)
✔️ Improves predictability of review and approval timelines
✔️ Enhances product quality and regulatory transparency

This regulatory update not only fosters scientific rigor in generic drug quality, but also enhances Japan’s integration with the global regulatory ecosystem –offering clearer pathways for sponsors eyeing entry or expansion into one of the world’s most important pharmaceutical markets.

Read the full blog to understand what steps your RA team should take to align with these new expectations: https://resource.ddregpharma.com/blogs/japan-implements-ich-guidelines-for-generic-drugs/


Comments

Post a Comment

Popular posts from this blog

Safety Reporting in the EU - EudraVigilance to EVDAS & SPOR

Image
  Safety Reporting in the EU With safety reporting in the European Union (EU) entering a new era of digital integration and oversight, pharmacovigilance systems have become more connected, data-driven, and strategically central to  regulatory compliance . What once revolved around manual case handling and isolated national databases has transformed into a highly interconnected pharmacovigilance network. This shift is not only redefining how  Marketing Authorisation Holders  (MAHs) manage  Individual Case Safety Reports  (ICSRs), but it’s also reshaping their overall safety strategy. The regulatory landscape has gone far beyond the central  EudraVigilance  system. Tools like EVDAS (EudraVigilance Data Analysis System) and SPOR (Substance, Product, Organisation, and Referential data services) have become central to pharmacovigilance compliance. However, with increased automation, transparency, and interconnectivity come greater complexity and respon...
Read more

Risk Management in Regulatory Affairs: Mitigating Compliance Risks

Image
Pharmaceutical companies face significant challenges in navigating a stringent and constantly evolving regulatory environment, coupled with technological advancements and global economic considerations. Assessing and managing risks is vital throughout the entire life cycle of a pharmaceutical product, from research and clinical testing to manufacturing and distribution. Organizations must demonstrate to regulatory authorities that they have a well-documented plan to identify, measure, control, and monitor the various risks. The pharmaceutical industry is highly regulated for good reason, given the critical importance of safety, efficacy, and the impact that medicines and treatments can have on patient’s lives. Regulatory scrutiny spans various aspects of pharmaceutical operations, including sales and marketing, drug price reporting, patient privacy, clinical trials and procedures, preclinical work and testing, and manufacturing. Consequently, ensuring compliance with regulatory affairs...
Read more

Customer Due Diligence: Meeting Regulatory Expectations

Image
In today's business landscape, regulatory compliance is a cornerstone of trust and integrity. Nowhere is this more evident than in the realm of customer due diligence (CDD). Financial institutions, businesses dealing with high-value transactions, and even online platforms must adhere to stringent CDD requirements to mitigate risks associated with money laundering, terrorism financing, and other illicit activities. Meeting regulatory expectations in CDD is not just about ticking boxes; it's about safeguarding against financial crime while fostering trust with customers. Let's delve into how businesses can navigate this complex landscape effectively. Understanding Customer Due Diligence Customer due diligence refers to the process of verifying the identity of customers, assessing the risks they pose, and understanding the nature of their transactions. It involves collecting relevant information about customers, such as their identity, address, and source of funds, to ensure c...
Read more